Jennifer Marie Pursley, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bilirubin | 1 | 2020 | 435 | 0.610 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 6 | 2024 | 1655 | 0.600 |
Why?
|
| Serum Albumin | 1 | 2020 | 672 | 0.550 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2024 | 801 | 0.510 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2023 | 2291 | 0.310 |
Why?
|
| Uncertainty | 1 | 2012 | 752 | 0.290 |
Why?
|
| Photons | 3 | 2021 | 589 | 0.280 |
Why?
|
| Radiotherapy Dosage | 5 | 2024 | 2897 | 0.270 |
Why?
|
| Models, Statistical | 1 | 2020 | 5073 | 0.250 |
Why?
|
| Liver | 2 | 2022 | 7512 | 0.250 |
Why?
|
| Liver Neoplasms | 4 | 2023 | 4308 | 0.240 |
Why?
|
| Brachytherapy | 1 | 2012 | 1223 | 0.240 |
Why?
|
| Protons | 4 | 2023 | 1112 | 0.240 |
Why?
|
| Seminoma | 1 | 2023 | 134 | 0.210 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 2894 | 0.200 |
Why?
|
| Titanium | 1 | 2023 | 485 | 0.170 |
Why?
|
| Lymphopenia | 1 | 2022 | 281 | 0.170 |
Why?
|
| Organs at Risk | 2 | 2021 | 359 | 0.160 |
Why?
|
| Radiometry | 2 | 2023 | 812 | 0.150 |
Why?
|
| Prostatic Neoplasms | 3 | 2021 | 11106 | 0.140 |
Why?
|
| Radiation Protection | 1 | 2021 | 424 | 0.140 |
Why?
|
| Testicular Neoplasms | 1 | 2023 | 800 | 0.140 |
Why?
|
| Prostate | 3 | 2021 | 1773 | 0.140 |
Why?
|
| Liver Failure | 1 | 2019 | 250 | 0.140 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 596 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2023 | 1051 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 8998 | 0.130 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 833 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2021 | 1189 | 0.110 |
Why?
|
| Intraoperative Period | 1 | 2012 | 510 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2019 | 1339 | 0.080 |
Why?
|
| Subtraction Technique | 1 | 2012 | 512 | 0.080 |
Why?
|
| Organ Size | 1 | 2012 | 2252 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2012 | 994 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2012 | 2326 | 0.060 |
Why?
|
| Orchiectomy | 1 | 2023 | 463 | 0.050 |
Why?
|
| Humans | 15 | 2024 | 760617 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5319 | 0.040 |
Why?
|
| Lung | 1 | 2019 | 9998 | 0.040 |
Why?
|
| Blood Cells | 1 | 2021 | 305 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 29600 | 0.040 |
Why?
|
| Inflammation | 1 | 2019 | 10760 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 3356 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 1784 | 0.040 |
Why?
|
| Male | 8 | 2023 | 360358 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 58894 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2021 | 659 | 0.040 |
Why?
|
| Rectum | 1 | 2021 | 891 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2020 | 80566 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2022 | 1257 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 36402 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 13382 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2023 | 2518 | 0.030 |
Why?
|
| Artifacts | 1 | 2023 | 1910 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2022 | 2604 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2023 | 20556 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 9277 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2021 | 1956 | 0.030 |
Why?
|
| Aged | 3 | 2020 | 169042 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 8516 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 14018 | 0.020 |
Why?
|
| Middle Aged | 3 | 2020 | 220584 | 0.020 |
Why?
|
| Swine | 1 | 2021 | 5907 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 8166 | 0.020 |
Why?
|
| Female | 4 | 2022 | 392148 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 11116 | 0.020 |
Why?
|
| Cause of Death | 1 | 2019 | 3683 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 10073 | 0.020 |
Why?
|
| Adult | 1 | 2020 | 220969 | 0.020 |
Why?
|
| Rats | 1 | 2021 | 23717 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 12447 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 2689 | 0.010 |
Why?
|
| Disease Progression | 1 | 2019 | 13495 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 18221 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2012 | 2881 | 0.010 |
Why?
|
| Incidence | 1 | 2019 | 21337 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39063 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 14648 | 0.010 |
Why?
|
| Neoplasms | 1 | 2024 | 22131 | 0.010 |
Why?
|
| Risk Factors | 1 | 2022 | 74115 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 20074 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 64568 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 168201 | 0.000 |
Why?
|